152 related articles for article (PubMed ID: 35574423)
1. Case Report: Short-Term Response to First-Line Crizotinib Monotherapy in a Metastatic Lung Adenocarcinoma Patient Harboring a Novel
Wei S; Hu M; Yang Y; Huang X; Li B; Ding L; Wang P
Front Oncol; 2022; 12():862008. PubMed ID: 35574423
[No Abstract] [Full Text] [Related]
2. BRAF V600E Mediates Crizotinib Resistance and Responds to Dabrafenib and Trametinib in a ROS1-Rearranged Non-Small Cell Lung Cancer: A Case Report.
Li J; Wang Q; Ge J; Tian Y; Yao W
Oncologist; 2021 Dec; 26(12):e2115-e2119. PubMed ID: 34516041
[TBL] [Abstract][Full Text] [Related]
3.
Cheng Y; Yang J; Wang D; Yan D
Ann Transl Med; 2022 Feb; 10(3):157. PubMed ID: 35284560
[No Abstract] [Full Text] [Related]
4. Identification of a Novel MPRIP-ROS1 Fusion and Clinical Efficacy of Crizotinib in an Advanced Lung Adenocarcinoma Patient: A Case Report.
Shu Y; Li H; Shang H; Chen J; Su X; Le W; Lei Y; Tao L; Zou C; Wu W
Onco Targets Ther; 2020; 13():10387-10391. PubMed ID: 33116618
[TBL] [Abstract][Full Text] [Related]
5. Case report: Successful sequential therapy of crizotinb and entrectinib in ROS1-positive non-small-cell lung cancer with brain metastasis in later-settings.
Dong W; Zhuge J; Yu P; Liu K; Yang M; Wang H
Medicine (Baltimore); 2023 Dec; 102(51):e36591. PubMed ID: 38134118
[TBL] [Abstract][Full Text] [Related]
6. Entrectinib Response to ROS1-Fusion-Positive Non-Small-Cell Lung Cancer That Progressed on Crizotinib with Leptomeningeal Metastasis: A Case Report.
Sawada H; Taniguchi Y; Iizuka S; Ikeda T; Aga M; Hamakawa Y; Miyazaki K; Misumi Y; Agemi Y; Nakamura Y; Maeda K; Shimokawa T; Okamoto H
Case Rep Oncol; 2023; 16(1):1558-1567. PubMed ID: 38089732
[TBL] [Abstract][Full Text] [Related]
7. Case Report: Response to crizotinib treatment in a patient with advanced non-small cell lung cancer with
Shu Y; Wang Z; Shang H; Le W; Lei Y; Huang L; Tao L; Chen J; Li J
Front Oncol; 2023; 13():1169876. PubMed ID: 37152007
[TBL] [Abstract][Full Text] [Related]
8. Identification of a novel WNK1-ROS1 fusion in a lung adenocarcinoma sensitive to crizotinib.
Liu Y; Liu T; Li N; Wang T; Pu Y; Lin R
Lung Cancer; 2019 Mar; 129():92-94. PubMed ID: 30797499
[TBL] [Abstract][Full Text] [Related]
9. ROS1-fusion protein induces PD-L1 expression via MEK-ERK activation in non-small cell lung cancer.
Liu Z; Zhao K; Wei S; Liu C; Zhou J; Gou Q; Wu X; Yang Z; Yang Y; Peng Y; Cheng Q; Liu L
Oncoimmunology; 2020 May; 9(1):1758003. PubMed ID: 32923114
[TBL] [Abstract][Full Text] [Related]
10. Clinical activity of brigatinib in ROS1-rearranged non-small cell lung cancer.
Dudnik E; Agbarya A; Grinberg R; Cyjon A; Bar J; Moskovitz M; Peled N;
Clin Transl Oncol; 2020 Dec; 22(12):2303-2311. PubMed ID: 32462394
[TBL] [Abstract][Full Text] [Related]
11. ROS1-ADGRG6: a case report of a novel ROS1 oncogenic fusion variant in lung adenocarcinoma and the response to crizotinib.
Xu S; Wang W; Xu C; Li X; Ye J; Zhu Y; Ge T
BMC Cancer; 2019 Aug; 19(1):769. PubMed ID: 31382924
[TBL] [Abstract][Full Text] [Related]
12. Case Report: Detection of Double ROS1 Translocations,
Xu L; Chen X; Huo H; Liu Y; Yang X; Gu D; Yuan M; Zhang M; Chen R; Wang J; Zheng Z
Front Med (Lausanne); 2021; 8():649177. PubMed ID: 34616749
[No Abstract] [Full Text] [Related]
13. Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers.
Facchinetti F; Loriot Y; Kuo MS; Mahjoubi L; Lacroix L; Planchard D; Besse B; Farace F; Auger N; Remon J; Scoazec JY; André F; Soria JC; Friboulet L
Clin Cancer Res; 2016 Dec; 22(24):5983-5991. PubMed ID: 27401242
[TBL] [Abstract][Full Text] [Related]
14. Small cell transformation in crizotinib-resistant ROS1-rearranged non-small cell lung cancer with retention of ROS1 fusion: A case report.
Wu CH; Su PL; Hsu CW; Chu CY; Lin CC
Thorac Cancer; 2021 Nov; 12(22):3068-3071. PubMed ID: 34623764
[TBL] [Abstract][Full Text] [Related]
15. Clinical and molecular factors that impact the efficacy of first-line crizotinib in ROS1-rearranged non-small-cell lung cancer: a large multicenter retrospective study.
Zhang Y; Zhang X; Zhang R; Xu Q; Yang H; Lizaso A; Xu C; Liu J; Wang W; Ou SI; Zhang J; Song Z; Yang N
BMC Med; 2021 Sep; 19(1):206. PubMed ID: 34511132
[TBL] [Abstract][Full Text] [Related]
16. First-line crizotinib versus platinum-pemetrexed chemotherapy in patients with advanced ROS1-rearranged non-small-cell lung cancer.
Shen L; Qiang T; Li Z; Ding D; Yu Y; Lu S
Cancer Med; 2020 May; 9(10):3310-3318. PubMed ID: 32167664
[TBL] [Abstract][Full Text] [Related]
17. ADK-VR2, a cell line derived from a treatment-naïve patient with
Ruzzi F; Angelicola S; Landuzzi L; Nironi E; Semprini MS; Scalambra L; Altimari A; Gruppioni E; Fiorentino M; Giunchi F; Ferracin M; Astolfi A; Indio V; Ardizzoni A; Gelsomino F; Nanni P; Lollini PL; Palladini A
Transl Lung Cancer Res; 2022 Nov; 11(11):2216-2229. PubMed ID: 36519016
[TBL] [Abstract][Full Text] [Related]
18. Clinical activity of crizotinib in lung adenocarcinoma harboring a
Kinoshita R; Nakao M; Kiyotoshi H; Hayashi S; Sugihara M; Hirata Y; Kuriyama M; Takeda N; Muramatsu H
Oncol Lett; 2023 Dec; 26(6):515. PubMed ID: 37927416
[TBL] [Abstract][Full Text] [Related]
19. Crizotinib presented with promising efficacy but for concomitant mutation in next-generation sequencing-identified ROS1-rearranged non-small-cell lung cancer.
Zeng L; Li Y; Xiao L; Xiong Y; Liu L; Jiang W; Heng J; Qu J; Yang N; Zhang Y
Onco Targets Ther; 2018; 11():6937-6945. PubMed ID: 30410351
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of Crizotinib among Different Types of ROS1 Fusion Partners in Patients with ROS1-Rearranged Non-Small Cell Lung Cancer.
Li Z; Shen L; Ding D; Huang J; Zhang J; Chen Z; Lu S
J Thorac Oncol; 2018 Jul; 13(7):987-995. PubMed ID: 29704675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
